Nanobiotechnology, defined as the application of nanotechnology in biology and medicine, refers to the use of nanometric structures to solve complex clinical problems through precise interaction at the molecular level. Nanostructures such as lipid, polymer, and metallic nanoparticles offer unique properties that enable improved therapeutic and diagnostic efficacy and the integration of diagnostic and therapeutic functions within the concept of theranostics. Major applications of nanobiotechnology include targeted drug delivery in cancer, infection, and gene therapy; advanced molecular diagnostics and biosensors; tissue engineering and regeneration; and immune system modulation through modern nanotechnology-based vaccines and immunotherapies. The clinical significance of these technologies lies in their ability to improve drug bioavailability, minimize adverse effects, increase sensitivity in early disease detection, and support personalized treatment strategies. Nanobiotechnology also contributes to the development of precision medicine by combining diagnostics and therapy within a single nanosystem. Despite promising results, significant challenges remain related to safety, biocompatibility, toxicity, and translation from laboratory studies to clinical applications. Further research is needed to standardize methods, assess the long-term health impact of nanomaterials, and develop regulatory frameworks to fully realize the potential of nanobiotechnology in medicine.
Kaznowska et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: